TY - JOUR
T1 - Predictive model for survival after liver resection for noncolorectal liver metastases in the modern era
T2 - a Japanese multicenter analysis
AU - Wakabayashi, Taiga
AU - Hibi, Taizo
AU - Yoneda, Godai
AU - Iwao, Yasuhito
AU - Sawada, Yu
AU - Hoshino, Hiroyuki
AU - Uemura, Shuichiro
AU - Ban, Daisuke
AU - Kudo, Atsushi
AU - Takemura, Yusuke
AU - Mishima, Kohei
AU - Shinoda, Masahiro
AU - Itano, Osamu
AU - Otsubo, Takehito
AU - Endo, Itaru
AU - Kitagawa, Yuko
AU - Tanabe, Minoru
AU - Egawa, Hiroto
AU - Yamamoto, Masakazu
N1 - Publisher Copyright:
© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: Survival benefit of liver resection for noncolorectal liver metastases (NCRLM) remains to be defined. Methods: This multicenter, retrospective cohort analysis included consecutive patients with NCRLM whose primary tumor and all metastases were treated with curative intent between 2000 and 2013. The primary endpoint was 5-year overall survival. Clinicopathological factors that affected prognoses were identified using multivariate Cox regression analyses and were included in a predictive model. Results: Data for 205 patients were analyzed. The three most common primary tumor sites were stomach (39%), pancreas (13%), and urinary tract (10%), with adenocarcinomas the main pathology (52%). R0 resection was achieved in 85%, and the overall survival at 5 years was 41%. In the multivariate analysis, synchronous liver metastases, R1/2 resection, and adenocarcinomas and other carcinomas (with gastrointestinal stromal tumors, neuroendocrine tumors G1/G2, and sarcomas set as the reference group) were independent negative indicators of overall survival. A predictive model effectively stratified the NCRLM patients into low-, intermediate-, and high-risk groups with overall 5-year survival rates of 63%, 38%, and 21%, respectively (P < 0.001). Conclusions: Patients who underwent curative resection for metachronous disease and favorable tumor pathology are expected to have better survival in the NCRLM cohort.
AB - Background: Survival benefit of liver resection for noncolorectal liver metastases (NCRLM) remains to be defined. Methods: This multicenter, retrospective cohort analysis included consecutive patients with NCRLM whose primary tumor and all metastases were treated with curative intent between 2000 and 2013. The primary endpoint was 5-year overall survival. Clinicopathological factors that affected prognoses were identified using multivariate Cox regression analyses and were included in a predictive model. Results: Data for 205 patients were analyzed. The three most common primary tumor sites were stomach (39%), pancreas (13%), and urinary tract (10%), with adenocarcinomas the main pathology (52%). R0 resection was achieved in 85%, and the overall survival at 5 years was 41%. In the multivariate analysis, synchronous liver metastases, R1/2 resection, and adenocarcinomas and other carcinomas (with gastrointestinal stromal tumors, neuroendocrine tumors G1/G2, and sarcomas set as the reference group) were independent negative indicators of overall survival. A predictive model effectively stratified the NCRLM patients into low-, intermediate-, and high-risk groups with overall 5-year survival rates of 63%, 38%, and 21%, respectively (P < 0.001). Conclusions: Patients who underwent curative resection for metachronous disease and favorable tumor pathology are expected to have better survival in the NCRLM cohort.
KW - Gastric carcinoma
KW - Liver resection
KW - Noncolorectal liver metastasis
KW - Pancreatic carcinoma
KW - Survival rate
UR - http://www.scopus.com/inward/record.url?scp=85072993873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072993873&partnerID=8YFLogxK
U2 - 10.1002/jhbp.654
DO - 10.1002/jhbp.654
M3 - Article
C2 - 31271511
AN - SCOPUS:85072993873
SN - 1868-6974
VL - 26
SP - 441
EP - 448
JO - Journal of Hepato-Biliary-Pancreatic Sciences
JF - Journal of Hepato-Biliary-Pancreatic Sciences
IS - 10
ER -